Canadian Biosimilars Industry Urges Ontario To Switch
Biosimilars Canada Once Again Calls On Province To Follow Example Of Others
Biosimilars Canada has renewed its call for Ontario to adopt a biosimilar switching policy in line with other Canadian provinces and territories, suggesting that Ontario alone could save CAD147m annually through such a scheme.
You may also be interested in...
Newfoundland and Labrador has become the ninth jurisdiction in Canada to implement a biosimilar switching policy for patients enrolled on its public health program.
Ontario has joined several other Canadian provinces and territories by implementing a biosimilar switching policy for Ontarians taking biologic drugs.
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.